The board of Sanofi India Limited (SIL) approved its standalone and consolidated financial results, for Q4 and year to date ended on December 31st, 2024, after the demerger of its consumer healthcare business effective from June 1st, 2024.

Diabetes portfolio reported double digit growth for Toujeo and successful launch of Soliqua reinstating confidence and strength in our comprehensive diabetes portfolio.

The recently announced partnerships for CNS (Central Nervous System) and the CV (Cardiovascular) brands have established their foundation for acceleration, expansion in reach and achievement were as expectation.

The Company was able to increase its operating profit in Q4-2024 by 21% vs Q4-2023. The Profit from Operations for Q4-2024 was at Rs. 108 crore versus Rs. 90 crore Q4-2023.

The company continues to make good progress on its ‘India for India’ strategy through go-tomarket initiatives, improving operating efficiency and promoting innovation.

Rodolfo Hrosz, Managing Director, Sanofi India Limited, “In a year of significant transformation for the company, we have successfully brought to market Soliqua - our best-in-class diabetes drug for the premix segment, which has received encouraging acceptance. Our efforts of reaching more HCPs through partnerships for the Cardiovascular and CNS (Central Nervous System) categories have advanced as planned, with initial promising results. We will continue to focus on driving further improvement in operating efficiencies while expanding the availability of established and innovative products in India.”